PURPOSE: Targeted oncolytic adenoviruses capable of replication selectively in cancer cells are an appealing approach for the treatment of various cancer types refractory to conventional therapies. The aim of this study was to evaluate the effect of Ad5/3MDR1E1, a multidrug resistance gene 1 (MDR1)-targeted fiber-modified replication-competent adenovirus for the therapy of platinum-pretreated ovarian cancer in combination with cytostatic agents. METHODS: MDR1-specific tumor cell killing of Ad5/3MDR1E1 was systematically evaluated in chemotherapy naïve and pretreated ovarian cancer cells in vitro. Combinations of Ad5/3MDR1E1 and cytostatic agents were studied in vivo and in vitro. An in vivo hepatotoxicity model was used to evaluate liver toxicity. RESULTS: We demonstrate efficient oncolysis of Ad5/3MDR1E1 in chemotherapy-resistant ovarian cancer cells as well as therapeutic efficacy in an orthotopic mouse model. Further, combining Ad5/3MDR1E1 with paclitaxel resulted in greater therapeutic benefit than either agent alone. CONCLUSION: These preclinical data suggest that a fiber-modified adenovirus vector under the control of the MDR1 promoter represents a promising treatment strategy for platinum-pretreated ovarian cancer as a single agent or in combination with conventional anticancer drugs.
PURPOSE: Targeted oncolytic adenoviruses capable of replication selectively in cancer cells are an appealing approach for the treatment of various cancer types refractory to conventional therapies. The aim of this study was to evaluate the effect of Ad5/3MDR1E1, a multidrug resistance gene 1 (MDR1)-targeted fiber-modified replication-competent adenovirus for the therapy of platinum-pretreated ovarian cancer in combination with cytostatic agents. METHODS:MDR1-specific tumor cell killing of Ad5/3MDR1E1 was systematically evaluated in chemotherapy naïve and pretreated ovarian cancer cells in vitro. Combinations of Ad5/3MDR1E1 and cytostatic agents were studied in vivo and in vitro. An in vivo hepatotoxicity model was used to evaluate liver toxicity. RESULTS: We demonstrate efficient oncolysis of Ad5/3MDR1E1 in chemotherapy-resistant ovarian cancer cells as well as therapeutic efficacy in an orthotopic mouse model. Further, combining Ad5/3MDR1E1 with paclitaxel resulted in greater therapeutic benefit than either agent alone. CONCLUSION: These preclinical data suggest that a fiber-modified adenovirus vector under the control of the MDR1 promoter represents a promising treatment strategy for platinum-pretreated ovarian cancer as a single agent or in combination with conventional anticancer drugs.
Authors: Gerd J Bauerschmitz; John T Lam; Anna Kanerva; Kaori Suzuki; Dirk M Nettelbeck; Igor Dmitriev; Victor Krasnykh; Galina V Mikheeva; Mack N Barnes; Ronald D Alvarez; Peter Dall; Ramon Alemany; David T Curiel; Akseli Hemminki Journal: Cancer Res Date: 2002-03-01 Impact factor: 12.701
Authors: John L Jakubczak; Patricia Ryan; Mario Gorziglia; Lori Clarke; Lynda K Hawkins; Carl Hay; Ying Huang; Michele Kaloss; Anthony Marinov; Sandrina Phipps; Anne Pinkstaff; Pamela Shirley; Yelena Skripchenko; David Stewart; Suzanne Forry-Schaudies; Paul L Hallenbeck Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Arto Immonen; Matti Vapalahti; Kristiina Tyynelä; Heleena Hurskainen; Anu Sandmair; Ritva Vanninen; Gillian Langford; Neil Murray; Seppo Ylä-Herttuala Journal: Mol Ther Date: 2004-11 Impact factor: 11.454
Authors: A M Puumalainen; M Vapalahti; R S Agrawal; M Kossila; J Laukkanen; P Lehtolainen; H Viita; L Paljärvi; R Vanninen; S Ylä-Herttuala Journal: Hum Gene Ther Date: 1998-08-10 Impact factor: 5.695
Authors: A G Zeimet; E Müller-Holzner; A Schuler; G Hartung; J Berger; M Hermann; M Widschwendter; J M Bergelson; C Marth Journal: Gene Ther Date: 2002-08 Impact factor: 5.250
Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694